Significant strides were made in 2024 in evaluating a wide range of treatments for migraine, including phase 2 findings with PACAP inhibition, PI McAllister said.
The onset of migraine with its wide range of symptoms may be telegraphed as early as 2 days before by the frequency of neuronal oscillation deep in the brain.
Agitation affects at least one half of adults with Alzheimer disease; geriatric psychiatrist Grossberg explains the symptoms and new treatments in this year's video series.
Panelists discuss how untreated obstructive sleep apnea (OSA) significantly increases patients’ risk of serious health complications, including cardiovascular disease, type 2 diabetes, depression, and cognitive impairment while exacerbating existing comorbidities.
Geriatric psychiatrist and neurocognitive researcher George Grossberg, MD, highlights the mechanism of action for the new dextromethorphan/bupropion combination.
Todd W. Frieze, MD, discusses the therapeutic role of TSH suppression in differentiated thyroid cancer, as well as treatment goals and ongoing surveillance strategies.
Alex Tessnow, MD, reviews the presentation of hypothyroidism among elderly patients and outlines key considerations for treatment.
Panelists discuss how delaying intervention during Stage 2 Type 1 diabetes increases the risk of diabetic ketoacidosis and complications at diagnosis, while also potentially accelerating beta cell destruction and reducing the window for preservation therapies.
Panelists discuss how Type 1 diabetes progresses through distinct stages, from initial autoimmunity with normal blood glucose (Stage 1), to dysglycemia without symptoms (Stage 2), to clinical diagnosis with symptoms (Stage 3), marking critical intervention points for treatment and management.
Panelists discuss how screening for Type 1 diabetes should focus on identifying high-risk individuals through family history, genetic markers, and autoantibody testing, while emphasizing the importance of early detection to prevent diabetic ketoacidosis at diagnosis.